Francis L. Coolidge’s Teva Pharmaceuticals TEVA Stock Holding History

Francis L. Coolidge’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$60K	Buy	+1,519	New	+$59.2K	0.07%	143

Other funds holding TEVA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Francis L. Coolidge's TEVA Position: Q2 2013 in Review

Francis L. Coolidge opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2013: 1,519 shares worth $60K. The stake represents 0.07% of the portfolio and ranks #143 among its holdings.

744 funds tracked by Wall St. Rank hold TEVA as of Q2 2013.

Francis L. Coolidge held 1,519 shares of Teva Pharmaceuticals worth $60K as of Q2 2013.
Teva Pharmaceuticals was a new Francis L. Coolidge position in Q2 2013.
Teva Pharmaceuticals made up 0.07% of Francis L. Coolidge's portfolio in Q2 2013, its #143 holding.
744 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2013.

Based on Francis L. Coolidge's 13F filing for Q2 2013, filed 7 Aug 2013.